Moderate

IgA nephropathy (Berger disease) — mesangial IgA glomerulonephritis

Glomerular disease · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Commonest primary glomerulonephritis worldwide (high prevalence in East Asia; common in South Asia). Mesangial deposition of galactose-deficient IgA1 immune complexes. Classic presentations: synpharyngitic visible (macroscopic) haematuria within 1-2 days of a mucosal infection (vs ~2 weeks in post-strep GN), or incidental microscopic haematuria + proteinuria. Course ranges from benign to progressive CKD; a minority present with RPGN/crescentic disease or AKI. Management centres on maximal supportive kidney-protective therapy, with immunosuppression reserved for high-risk/progressive disease.

Red flags

  • Rapidly rising creatinine with RBC casts — crescentic/RPGN transformation, urgent biopsy + immunosuppression
  • AKI following an episode of visible haematuria (ATN from tubular haem pigment, or crescents)
  • Malignant hypertension
  • Nephrotic-range proteinuria (may indicate coexisting minimal-change lesion or advanced disease)
  • Older patient with new visible haematuria — exclude urological malignancy before attributing to IgAN

Assessment

Differential diagnosis

  • Post-infectious (post-streptococcal) GN — latent period ~1-3 weeks, low C3, raised ASOT
  • IgA vasculitis (Henoch-Schonlein) — same deposits plus purpura/arthritis/GI involvement
  • Thin basement membrane disease / Alport (familial haematuria)
  • Other causes of glomerular haematuria (lupus, MPGN, anti-GBM)
  • Urological causes of visible haematuria (stones, tumour, UTI) — exclude in older patients

Investigations

  • Urine microscopy (dysmorphic RBCs, red cell casts), urine PCR/ACR to quantify proteinuria
  • U&E/creatinine/eGFR trend; BP
  • Complement C3/C4 (typically normal in IgA, low in post-strep/MPGN/lupus), ASOT/anti-DNase B, ANA, ANCA/anti-GBM if rapid decline
  • HBV/HCV/HIV; serum IgA (raised in a minority, not diagnostic)
  • Renal ultrasound; renal biopsy for diagnosis + MEST-C Oxford score (prognostic) when proteinuria/impairment or diagnostic uncertainty
  • If AKI/RPGN picture: urgent biopsy to identify crescents

Management

  • Confirm diagnosis on biopsy where there is proteinuria, impaired/declining eGFR or uncertainty; score MEST-C for prognosis
  • Maximal supportive (kidney-protective) care first-line: BP control to <=120/70 mmHg where tolerated, maximally titrated ACEi or ARB to reduce proteinuria, lifestyle (salt restriction, smoking cessation, weight)
  • Add an SGLT2 inhibitor for persistent proteinuria/CKD (as per CKD evidence) — now standard supportive therapy
  • Reassess proteinuria after optimised supportive therapy; identify patients at high risk of progression (persistent proteinuria >0.75-1 g/day despite optimisation, declining eGFR, adverse MEST-C)
  • For high-risk progressive disease, discuss disease-targeted therapy: a 9-month course of targeted-release budesonide (Nefecon), or a reduced-dose systemic glucocorticoid regimen with infection (PCP) prophylaxis where Nefecon unavailable (KDIGO 2025)
  • Consider endothelin receptor antagonist (sparsentan) as an alternative to RAS blockade to reduce proteinuria in appropriate patients (avoid in pregnancy — teratogenic) [verify local availability]
  • Treat crescentic/RPGN variant aggressively (steroids +/- cyclophosphamide) as for RPGN; manage AKI supportively
  • Long-term nephrology follow-up with periodic proteinuria/eGFR monitoring and CV risk reduction

Drugs & doses

Ramipril 2.5-10 mg PO once daily OR losartan 50-100 mg PO once daily, titrated to max tolerated for anti-proteinuric effect and BP <=120/70 [verify local dose]
Dapagliflozin 10 mg PO once daily (add to RAS blockade for persistent proteinuria/CKD)
Targeted-release budesonide (Nefecon) 16 mg PO once daily for 9 months in high-risk progressive IgAN (KDIGO 2025) [verify local availability/dose]
Reduced-dose systemic glucocorticoid regimen (e.g. prednisolone, tapering per protocol) WITH co-trimoxazole PCP prophylaxis where Nefecon unavailable [verify local dose]
Sparsentan (dual endothelin/angiotensin receptor antagonist) as proteinuria-lowering alternative to RAS blockade — contraindicated in pregnancy [verify local availability/dose]
For crescentic/RPGN IgAN: IV methylprednisolone pulses + oral steroids +/- cyclophosphamide per RPGN protocol [verify local dose]

Disposition

Outpatient nephrology for most, with optimised supportive therapy and monitoring. Admit for AKI/RPGN, malignant hypertension or significant proteinuria needing urgent biopsy. Specialist decision on disease-targeted therapy for high-risk progressive disease.

Complications & pitfalls

  • Progressive CKD and kidney failure (up to ~20-40% over 10-20 years in biopsied cohorts)
  • Hypertension
  • Rapidly progressive (crescentic) glomerulonephritis
  • AKI (synpharyngitic haematuria-associated or crescentic)
  • Recurrence in renal transplant

Exam pearls

  • Synpharyngitic haematuria (haematuria at the SAME time as a sore throat/mucosal infection) points to IgAN; a 1-3 week latent period after pharyngitis/skin infection with LOW C3 points to post-streptococcal GN.
  • KDIGO 2025 IgAN guideline: optimise supportive therapy (RASi or endothelin receptor antagonist +/- SGLT2i, BP <=120/70) FIRST; reserve a 9-month Nefecon course or reduced-dose steroids for those still at risk of progression.
  • C3 is characteristically NORMAL in IgA nephropathy — a persistently low C3 should prompt reconsideration (post-strep, lupus, MPGN).
  • MEST-C Oxford histological score guides prognosis and the immunosuppression decision — the biopsy is worth it when there is proteinuria or impairment.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.